NCT00956644 - Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy | Biotech Hunter

Enrollment

406

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Hypertension

Interventions

DRUG

irbesartan/amlodipine

Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning

DRUG

amlodipine

Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning

Trial Locations (40)

5000

Sanofi-Aventis Investigational Site Number 78803, Monastir

34080

Sanofi-Aventis Investigational Site Number 48401, Durango

44656

Sanofi-Aventis Investigational Site Number 48402, Guadalajara

Sanofi-Aventis Investigational Site Number 48403, Guadalajara

44670

Sanofi-Aventis Investigational Site Number 48406, Guadalajara

44680

Sanofi-Aventis Investigational Site Number 48404, Guadalajara

13059-900

Sanofi-Aventis Investigational Site Number 07602, Campinas

20551-030

Sanofi-Aventis Investigational Site Number 076-005, Rio de Janeiro

Sanofi-Aventis Investigational Site Number 07605, Rio de Janeiro

88103-460

Sanofi-Aventis Investigational Site Number 07604, São José

04025-011

Sanofi-Aventis Investigational Site Number 07601, São Paulo

04038-002

Sanofi-Aventis Investigational Site Number 076-004, São Paulo

05403-000

Sanofi-Aventis Investigational Site Number 076-002, São Paulo

Sanofi-Aventis Investigational Site Number 07603, São Paulo

Unknown

Sanofi-Aventis Investigational Site Number 15202, Santiago

Sanofi-Aventis Investigational Site Number 15203, Santiago

Sanofi-Aventis Investigational Site Number 15204, Santiago

Sanofi-Aventis Investigational Site Number 15205, Santiago

Sanofi-Aventis Investigational Site Number 15206, Santiago

Sanofi-Aventis Investigational Site Number 17003, Barranquilla

Sanofi-Aventis Investigational Site Number 17004, Barranquilla

Sanofi-Aventis Investigational Site Number 17002, Medellín

Sanofi-Aventis Investigational Site Number 81803, Alexandria

Sanofi-Aventis Investigational Site Number 81804, Alexandria

Sanofi-Aventis Investigational Site Number 81801, Cairo

Sanofi-Aventis Investigational Site Number 81802, Cairo

Sanofi-Aventis Investigational Site Number 42202, Beirut

Sanofi-Aventis Investigational Site Number 42203, Beirut

Sanofi-Aventis Investigational Site Number 42204, Beirut

Sanofi-Aventis Investigational Site Number 42205, Beirut

Sanofi-Aventis Investigational Site Number 42206, Beirut

Sanofi-Aventis Investigational Site Number 50401, Casablanca

Sanofi-Aventis Investigational Site Number 50402, Marrakesh

Sanofi-Aventis Investigational Site Number 50403, Marrakesh

Sanofi-Aventis Investigational Site Number 78804, Aryanah

Sanofi-Aventis Investigational Site Number 78802, Sfax

Sanofi-Aventis Investigational Site Number 78801, Tunis

Sanofi-Aventis Investigational Site Number 86201, Caracas

06140

Sanofi-Aventis Investigational Site Number 48405, México

07330

Sanofi-Aventis Investigational Site Number 48407, México